Company / SG&A Expense
Integra Lifesciences Holdings SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$699.7M
FY2025
5-year range
$616.3M / $717.0M
FY2021-FY2025
Trend
-2.4%
vs FY2024
Sector context
#56 of 158
Health Care
What the data says
At $700M, Integra Lifesciences Holdings's sg&a expense ranks #103 of 158 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $376M in FY2016 to $717M in FY2024.
Based on SEC 10-K filings.
$700M in FY2025 with a 5-year CAGR of +3.3%.
Increased from $657M to $700M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +4.3%
- 5-Year CAGR
- +3.3%
- 10-Year CAGR
- -
Sector benchmark
#103 of 158 in Health CareTop 65% of 158This company $699.7M Sector average $175.9B
▼
-99.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.3%, indicating consistent growth.
- In FY2025, sg&a expense decreased 2.4% year-over-year.
- Ranks #56 out of 158 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $699.7M | -2.4% |
| FY2024 | $717.0M | +9.2% |
| FY2023 | $656.6M | +6.5% |
| FY2022 | $616.3M | -3.3% |
| FY2021 | $637.4M | +7.2% |
| FY2020 | $594.5M | -13.5% |
| FY2019 | $687.6M | -0.5% |
| FY2018 | $690.7M | +66.1% |
| FY2017 | $415.8M | +10.7% |
| FY2016 | $375.5M | -9.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026